The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Adjuvant HER2+ Breast Cancer Care Evolves, But Questions Remain
October 9th 2015Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.
Lilly Expanding NYC Research Hub to Focus on Immunotherapy Combos
October 9th 2015Eli Lilly and Company is planning to expand its lab space at the Alexandria Center for Life Science in New York City to include a translational immuno-oncology hub that will serve as a "portal" for collaborating with researchers from nearby academic medical centers and biopharmaceutical companies.
PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma
October 7th 2015Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.
Laura and Isaac Perlmutter Cancer Center of NYU Langone Establishes Pioneering Program in Biologics
October 7th 2015Protein engineering expert Shohei Koide, PhD, appointed Director of Cancer Biologics at Perlmutter Cancer Center to lead groundbreaking new initiative in growing field of research and therapeutics
OncLive Welcomes The US Oncology Network as Newest Member of Strategic Alliance Partnership Program
October 6th 2015Collaboration to share the latest news from The US Oncology Network, a physician-led organization uniting top oncology practices across the nation to deliver high-quality, evidence-based cancer care
Cobimetinib/Vemurafenib Combo Improves Survival in Melanoma
October 6th 2015The combination of vemurafenib and cobimetinib demonstrated a statistically significant improvement in overall survival compared with vemurafenib alone for previously untreated patients with BRAFV600-mutant unresectable or metastatic melanoma.
Zoledronic Acid Does Not Add to Upfront Docetaxel Survival Benefit in Advanced Prostate Cancer
October 5th 2015An updated analysis of the STAMPEDE trial upholds the survival benefit observed with early use of docetaxel in advanced prostate cancer, but does not support the introduction of zoledronic acid.
FDA Schedules Advisory Meeting for MCNA in Bladder Cancer
October 2nd 2015The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.
Radiofrequency Ablation Dwell Time Significantly Impacts Survival in HCC
September 30th 2015Overall survival was improved by more than 25 months when lyso-thermosensitive liposomal doxorubicin was administered with optimized (≥45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.
Jeffrey Weber Joins NYU Langone, Plans to Expand Clinical Trial and Immunotherapy Initiatives
September 25th 2015Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.
Renowned Myeloma Expert Joins Mount Sinai
September 24th 2015Bart Barlogie, MD, world-renowned myeloma expert who introduced the first curative therapy, a multi-drug regimen known as Total therapy 3, for multiple myeloma joins the faculty of Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.
Daraprim Underscores Need for Drug Pricing Reform
September 24th 2015The attempt by Turing Pharmaceuticals to boost the price of the anti-parasitic pyrimethamine (Daraprim) 5500% is now under reconsideration, owing to a firestorm of public and institutional protest, but it doesn't solve the problem of no limits on what manufacturers can charge and the lack of drug pricing transparency.